Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

CureVac N.V (CVAC) EBIT Margin: 2019-2025

Historic EBIT Margin for CureVac N.V (CVAC) over the last 4 years, with Jun 2025 value amounting to -4,959.52%.

  • CureVac N.V's EBIT Margin fell 444954.00% to -4,959.52% in Q2 2025 from the same period last year, while for Jun 2025 it was 12.20%, marking a year-over-year increase of 45074.00%. This contributed to the annual value of 33.20% for FY2024, which is 54328.00% up from last year.
  • According to the latest figures from Q2 2025, CureVac N.V's EBIT Margin is -4,959.52%, which was up 19.07% from -6,128.44% recorded in Q1 2025.
  • Over the past 5 years, CureVac N.V's EBIT Margin peaked at 109.05% during Q3 2024, and registered a low of -6,128.44% during Q1 2025.
  • Its 3-year average for EBIT Margin is -1,714.67%, with a median of -719.58% in 2023.
  • In the last 5 years, CureVac N.V's EBIT Margin spiked by 109,222bps in 2022 and then tumbled by 553,589bps in 2025.
  • Quarterly analysis of 5 years shows CureVac N.V's EBIT Margin stood at -13.38% in 2021, then tumbled by 102,517bps to -1,038.55% in 2022, then soared by 64,910bps to -389.44% in 2023, then plummeted by 216,454bps to -2,553.99% in 2024, then crashed by 444,954bps to -4,959.52% in 2025.
  • Its EBIT Margin stands at -4,959.52% for Q2 2025, versus -6,128.44% for Q1 2025 and -2,553.99% for Q4 2024.